Key facts
- It has raised $24.0M; the latest was Later Stage VC ($70K) in Jul 2025.
- Notable investors include Keiretsu Forum, Robin Hood Ventures, Alliance of Angels, Crimson Peak, Keiretsu Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Virion Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Virion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Virion Therapeutics
Developer of novel immunotherapies designed to treat cancers and infectious diseases. The company's immunotherapies use targeted novel T-cell-based therapies that couple a checkpoint blockade with disease-specific antigenic stimulation, enabling physicians to prevent tumor or viral quasi-species escape.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2018
- Employees
- 7
- Website
- viriontx.com/
- Ownership
- Privately Held (backing)
Virion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Virion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Virion Therapeutics in its N-PORT filings yet. We sweep new filings monthly.